(Hypertension. 2000;35:1248.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From Instituto de Química y Fisicoquímica Biológicas (M.M.G., C.P.) and Cátedras de Fisiología (M.V.) y Fisiopatología (M.R.-F., B.E.F.), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina.
Correspondence to Dr Clara Peña, Instituto de Química y Fisicoquímica Biológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, 1113-Buenos Aires, Argentina. E-mail clara{at}qb.ffyb.uba.ar
AbstractAngiotensin
(Ang)-(1-7) elicits a facilitatory presynaptic effect on
peripheral noradrenergic neurotransmission,
and because biological responses to the heptapeptide on occasion are
tissue specific, the present investigation was undertaken to study
its action on noradrenergic neurotransmission at the
central level. In rat hypothalamus labeled with
[3H]-norepinephrine, 100 to 600 nmol/L
Ang-(1-7) diminished norepinephrine released by 25
mmol/L KCl. This effect was blocked by the selective
angiotensin type 2 receptor antagonist PD
123319 (1 µmol/L) and by the specific Ang-(1-7) receptor
antagonist [D-Ala7]Ang-(1-7)
(1 µmol/L) but not by losartan (10 nmol/L to 1
µmol/L), a selective angiotensin type 1 receptor
antagonist. The inhibitory effect on
noradrenergic neurotransmission caused by Ang-(1-7) was
prevented by 10 µmol/L
N
-nitro-L-arginine
methylester, an inhibitor of nitric oxide synthase
activity, and was restored by 100 µmol/L L-arginine,
precursor of nitric oxide synthesis. Methylene blue (10 µmol/L),
an inhibitor of guanylate cyclase considered as
the target of nitric oxide action, as well as Hoe 140 (10
µmol/L), a bradykinin B2-receptor antagonist,
prevented the inhibitory effect of the heptapeptide on
neuronal norepinephrine release, whereas no modification
was observed in the presence of 0.1 to 10 µmol/L
indomethacin, a cyclooxygenase
inhibitor. Our results indicate that Ang-(1-7) has a
tissue-specific neuromodulatory effect on noradrenergic
neurotransmission, being inhibitory at the central nervous
system by a nitric oxidedependent mechanism that involves
angiotensin type 2 receptors and local bradykinin
production.
Key Words: angiotensin norepinephrine nitric oxide angiotensin antagonist bradykinin prostaglandins
This article has been cited by other articles:
![]() |
L. K. Becker, G. M. Etelvino, T. Walther, R. A. S. Santos, and M. J. Campagnole-Santos Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1416 - H1424. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tsuda, I. Nishio, and M. M. Gironacci Angiotensin-(1-7) and Bradykinin in Norepinephrine Release in the Central Nervous System of Hypertension Hypertension, February 1, 2005; 45(2): e8 - e8. [Full Text] [PDF] |
||||
![]() |
M. M. Gironacci, M. S. Valera, I. Yujnovsky, and C. Pena Angiotensin-(1-7) Inhibitory Mechanism of Norepinephrine Release in Hypertensive Rats Hypertension, November 1, 2004; 44(5): 783 - 787. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |